Products
Apamistamab Biosimilar Radiolabelled Antibody (CD45) for Research
Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
The investigational drug 131-I apamistamab is a protein combined with a radioactive form of iodine, which gives off a small amount of radiation. ... It kills them, which prevents them from making other proteins associated with the side effects seen in some people who receive CAR T-cell therapy.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-029-1mg | 1mg | |
| GMP-Bios-ab-029-10mg | 10mg | |
| GMP-Bios-ab-029-100mg | 100mg | |
| GMP-Bios-ab-029-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Apamistamab biosimilar, Whole mAb Radiolabelled, Anti-PTPRC Antibody: Anti-B220/CD45/CD45R/GP180/L-CA/LCA/LY5/T200 therapeutic antibody |
| INN Name | Apamistamab |
| Target | PTPRC |
| Format | Whole mAb Radiolabelled |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | Actinium Pharmaceuticals;Fred Hutchinson Cancer Research Center |
| Conditions Approved | na |
| Conditions Active | Acute myeloid leukaemia;Myelodysplastic syndromes;Precursor cell lymphoblastic leukaemia-lymphoma |
| Conditions Discontinued | Hodgkin's disease;Non-Hodgkin's lymphoma |
| Development Tech | na |
About target - PTPRC
1. Protein Receptor-type tyrosine-protein phosphatase C
2. Gene PTPRC
3. Organism Homo sapiens (Human)
Function
Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity (By similarity).
(Microbial infection) Acts as a receptor for human cytomegalovirus protein UL11 and mediates binding of UL11 to T-cells, leading to reduced induction of tyrosine phosphorylation of multiple signaling proteins upon T-cell receptor stimulation and impaired T-cell proliferation.
Caution
It is uncertain whether Met-1 or Met-3 is the initiator.
Catalytic activity
H2O + O-phospho-L-tyrosyl-[protein] = L-tyrosyl-[protein] + phosphate
EC:3.1.3.48
